Last reviewed 2026-05-18 · How we verify

Inositol high volume

NICHD Neonatal Research Network · Phase 2 active Small molecule Quality 40/100

Inositol high volume is a Nutritional supplement Small molecule drug developed by NICHD Neonatal Research Network. It is currently in Phase 2 development. Also known as: Myo-inositol 5%.

Inositol acts as a precursor for phosphatidylinositol synthesis, supporting cellular membrane function and pulmonary surfactant production.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Inositol high volume
Also known as	Myo-inositol 5%
Sponsor	NICHD Neonatal Research Network
Drug class	Nutritional supplement
Modality	Small molecule
Phase	Phase 2

Mechanism of action

Inositol is incorporated into phospholipids and participates in intracellular signaling pathways. In neonates, it may enhance lung maturation by promoting surfactant synthesis and reducing inflammatory responses in developing lung tissue.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Inositol high volume CI brief — competitive landscape report
Inositol high volume updates RSS · CI watch RSS
NICHD Neonatal Research Network portfolio CI

Frequently asked questions about Inositol high volume

What is Inositol high volume?

Inositol high volume is a Nutritional supplement drug developed by NICHD Neonatal Research Network.

How does Inositol high volume work?

Inositol acts as a precursor for phosphatidylinositol synthesis, supporting cellular membrane function and pulmonary surfactant production.

Who makes Inositol high volume?

Inositol high volume is developed by NICHD Neonatal Research Network (see full NICHD Neonatal Research Network pipeline at /company/nichd-neonatal-research-network).

Is Inositol high volume also known as anything else?

Inositol high volume is also known as Myo-inositol 5%.

What drug class is Inositol high volume in?

Inositol high volume belongs to the Nutritional supplement class. See all Nutritional supplement drugs at /class/nutritional-supplement.

What development phase is Inositol high volume in?

Inositol high volume is in Phase 2.

Drug class: All Nutritional supplement drugs
Manufacturer: NICHD Neonatal Research Network — full pipeline
Also known as: Myo-inositol 5%

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing